Refine
Estimated Years 2000-2009Clear
2,481 results foundRefine Search
/VUA6 _ 134-6 Telomer Research Program V ^ Clariant Report Title: Purified 8-2 Alcohol: Salmonella - Escherichia co///M ammalian - M icrosome Reverse Mutation Assay with a Confirmatory Assay Author(s): Leon F.
Document imageDocument image
refid# ZJ8MvEG0R9qneGK3bvv289vMZ2 pages
SAMPLING INVESTIGATION RESULTS LITTLE HOCKING WATER ASSOCIATION WELL FIELD WASHINGTON COUNTY, OHIO Date: April 2003 Project No.: 7482 18983762.00010 A CORPORATE REMEDIATION GROUP An Alliance between DuPont and URS Diamond Barley Mill Plaza, Building 27 Wilmington, Delaware 19805 00030J.
Document imageDocument imageDocument imageDocument image
refid# g2N5BnjRem6zEOVwYjzN6RDbJ83 pages
S R P T T -74H MIN 315/022356 PERFLUOROOCTANESULFONYL FLUORIDE (POSF) T 'lf c ^ l.3 IN VITRO M AM M ALIAN CHROM OSOM E ABERRATION TEST IN HUMAN LYM PHOCYTES Sponsor 3M Center 3M Corporate Toxicology Building 220-2E-02 St Paul MN 55133-3220 USA - n e /sc-i Page 1 of 31 Research Laboratory Huntingdon Life Sciences Ltd Woolley Road Alconbury Huntingdon Cambridgeshire PE28 4HS ENGLAND Report issued 22 October 2002 MIN 315/022356 CONTENTS Page CONTENTS................................................................................................................................. 2 COMPLIANCE WITH GOOD LABORATORY PRACTICE STANDARDS....................... 4 QUALITY ASSURANCE STATEMENT................................................................................. 5 RESPONSIBLE PERSONNEL.................................................................................................. 6 SUMMARY................................................................................................................................. 7 INTRODUCTION........................................................................................................................ 8 TEST SUBSTANCE.................................................................................................................... 10 EXPERIMENTAL PROCEDURE.............................................................................................. 11 ASSESSMENT OF RESULTS................................................................................................... 15 MAINTENANCE OF RECORDS............................................................................................. 15 RESULTS..................................................................................................................................... 16 CONCLUSION............................................................................................................................ 17 REFERENCES............................................................................................................................. 18 : 2: MIN 315/022356 COMPLIANCE WITH GOOD LABORATORY PRACTICE STANDARDS The study described in this report was conducted in compliance with the following Good Laboratory Practice standards, with the exceptions stated below, and I consider the data generated to be valid.
Document imageDocument imageDocument imageDocument image
refid# e57n4MdN0JjnQBbw5Oo08Ld6428 pages
3M General Offices mH?
Document image
refid# bBybmvD0Onkn8jzQRxdwgMx211 page
Larry R.
Document imageDocument imageDocument imageDocument image
refid# BvoydrjMGx8n5jGRE8r39kG8o4 pages
FROM LATHAM & WATKINS WASH DC #3 (THU) 4. 27'00 12:11/ST. 12:06/NO. 4261478959.
Document imageDocument imageDocument image
refid# oDxrYb6DmoqxYVqvmgGL3yq7g3 pages
SRPT T-6295.8, T-6316.4, T-6868.2, T-7071.1, T-7132.1 DT15-B 3M MEDICAL DEPARTMENT, CORPORATE TOXICOLOGY Title: Comparative Molecular Biology of Perfluorooctanesulfonate (PFOS, T-6295), N-ethyl perfhiorooctanesulfonamido ethanol (N-EtFOSE, T-6316), N-Ethyl perfluorooctanesulfonamide (N-EtFOSA, T-6868), Perfluorooctanesulfonamido acetate (FOSAA, T-7071), and/or Perfluorooctanesulfonamide (FOSA, T-7I32) of in Rats and Guinea Pigs following Oral dosing.
Document imageDocument imageDocument imageDocument image
refid# RjzgMgzz92KbO5Bkbxbp069Ra74 pages
Katherine E.
Document imageDocument image
refid# a1aBbX1j7DDjM48m8G5GeyrOa2 pages
AtL22rtf(>8 Bladder Cancer in Perfluorooctanesulfonyl Fluoride Manufacturing Workers Final Report Bruce H.
Document imageDocument imageDocument imageDocument image
refid# 3NoJBz0N4VBx06anm4x1JoGVy29 pages
TestResijilts AR226-2123 File:///C|/WINDuws/1emp/U-B-LL
Document imageDocument imageDocument imageDocument image
refid# LJkBQyedDoXaXb4RnoqygL12g49 pages
AR226-2285 Frank D S m ith 05/10/2002 02:42 P M To: Jam es F Riley/CL/DuPont@ DuPont, Catherine A Barton/AE/DuPont@DuPont, Kenneth N W ood/AE/DuPont@ DuPont, Craig L Bartletl/AE/DuPont@DuPont c c: Isidores JZan ikos/A E/D uP ont DuPont, M ichael J Lukas/AE/DuPontDuPont, R 0 3 3 E Austin/AE/DuPont@ DuPont@ DuPont, Bernard J Reilly/AE/DuPont@DuPont Subject: Parkersburg N ew s & Sentinel Coverage on C -8 Protective Level Circleville Team, In light of the new drinking water standard as discussed in the attached, we need to re-evaluate our sam pling plans for C ircleville.
Document imageDocument imageDocument image
refid# 6Rvz0kda1agQmnvpQrnaMVZ33 pages
AR226-2584 (BUSS DuPont Engineering May 7,2002 \ ' George R.
Document imageDocument imageDocument image
refid# 0OXqeo3OdoqjNXOEzyo0pgoV3 pages
IT08NEK S AI LAW m z a &_ * r r r "i:1.fl iI0: I ?
Document imageDocument imageDocument imageDocument image
refid# YGw7bZKVrV6ZZ55Od20VJOMvy15 pages
AR226-3584 January 18, 2006 18uo f* t # t , f!
Document image
refid# o9n7RY2r4r8VYy3Jw7X635woE1 page
Katherine E.
Document imageDocument image
refid# G6yjvQOvEQB0V3woN5O66x6V2 pages